Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

CIBC World Upgrades Atrix Laboratories


Atrix Laboratories (ATRX) says the Food and Drug Administration reversed its decicion and approved its generic version of an acne gel. CIBC World upgraded the stock.

Analyst Mara Goldstein says she is upgrading Atrix to sector outperform from sector perform on the positive catalyst generated by the FDA's approval of the company's Abbreviated New Drug Application for its generic version of Benzamycin acne gel. She notes expectations for the generics business have been low -- appropriately so in her view.

However, Goldstein says the FDA's reversing its earlier decision, granting the company approval for generic Benzamycin, gives her greater confidence in Atrix' regulatory prowess. She notes that Benzamycin had sales of $41 million in 2003.

She kept EPS estimates of 39 cents for 2004 and $1.10 for 2005. She has a $30 price target on the stock.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus